Latest News

MSCA 2017 Presidency conference ‘Mobility takes research further’

13 March 2017

Read more ...

aDDRess and CodeAge Final ITN Conference: Abstract book now online!

03 November 2016

Read more ...

Björn Schumacher presentation on BR alpha Campus

7 October 2016

Read more ...

Gallery

gallery prev2

(Click image to open the gallery)

Contact

Let us hear from you.
This email address is being protected from spambots. You need JavaScript enabled to view it. or complete our contact form.

Thanks to

sponsors1sponsors2sponsors3


Prof. Dr. Harald Mischak / Dr. Petra Zürbig
Mosaiques Diagnostics GmbH, Germany

Image

Mosaiques Diagnostics GmbH

Mellendorfer Strasse 7-9

30625 Hannover, Germany
mischak@mosaiques-diagnostics.com
Tel: +49 511 554 7440
www.mosaiques-diagnostics.com

Image

mischakHarald Mischak received his PhD from the Technical University of Vienna, Austria, in 1986. After postdoctoral work at the University of Vienna, he was a Fogarty Fellow at the NIH, USA. He continued as Group Leader at the GSF, Munich, Germany from 1993-1998. After one year at the NIDDK, NIH, he took up a position at the Medical School of Hannover in 1999, and founded Mosaiques diagnostics in 2002. Today, he is director of Mosaiques diagnostics and professor of proteomics and Systems Medicine at the University of Glasgow, and a worldwide leading authority in clinical proteome analysis, with more than 200 papers published in peer reviewed journals which have been cited over 13000 times (h-factor 61), and more than 100 patents filed.

Research interest:
Based on his experience on proteomics in basic research, he initiated the use of urinary proteomics and capillary electrophoresis coupled mass spectrometry for clinical application. Today he is a leading authority in clinical proteomics and biomarker identification. Among his achievement in this field are the development of guidelines for clinical proteome analysis, and the identification of proteomic biomarkers and biomarker-derived classifiers for a variety of diseases (e.g. cardiovascular disease, diabetes, chronic kidney disease, bladder and prostate cancer). Several of these are already in clinical use today. His main interest are the identification of additional biomarkers, and combining the knowledge on these with literature to establish models for molecular pathology, which would enable identification of appropriate therapeutic targets, and the implementation of “personalized medicine”.

zuerbigPetra Zürbig received her PhD in Chemistry from the RWTH Aachen in 1997. Between 1998 and 2001 she worked as a postdoctoral fellow on the isolation and characterization of orphan receptor ligands from human hemofiltrate and porcine brain at the Lower Saxony Institute for Peptide Research (IPF), Germany. Here she worked at the department of peptide analysis and achieved deep insight into sequence analysis of peptides via mass spectrometric approaches. She completed her mass spectrometric knowledge as scientist at BioVisioN AG, Germany from 2001-2002. In 2003 she took up the position as head of the proteomics laboratory at the Fraunhofer Institute of Toxicology and Experimental Medicine (ITEM), Germany. Since 2005 she holds the position as group leader of Mosaiques diagnostics GmbH. In addition, she is the project manager of all kidney disease and aging projects. In addition, she is one of the founding members of the DGPF (German Society of Proteome Research). She is one of 15 authors, who published most papers on clinical proteomics in the last 5 years. With this experience in protein/peptide analyses, she is an expert in the fields of proteomic and peptidomic approaches.

Research interests:
Over the years, Mosaiques has heavily invested R&D and has developed a unique technology on the basis of clinical proteome analysis, enabling the early and differential detection of cardiovascular, renal, and urogenital diseases. In close collaboration with several academic Institutes in Germany and abroad, Mosaiques is currently developing diagnostic tests for additional indications, such as Alzheimer´s disease, pancreatic cancer, and nephrotoxic effects of drugs. Diagnosis is accomplished by highly specific patterns of multiple simultaneously detected biomarkers (proteins/polypeptides) from patient samples obtained in a riskfree and painless procedure. Mosaiques state of the art research in biostatistics/bioinformatics has made possible to efficiently analyze large amounts of data within minutes. This vast wealth of information is expected to facilitate accurate diagnosis of diseases and enable effective therapy prior to serious organ damage.